Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 67, 1783-1792, February 15, 2007. doi: 10.1158/0008-5472.CAN-06-2258
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meister, S.
Right arrow Articles by Voll, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meister, S.
Right arrow Articles by Voll, R. E.

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Extensive Immunoglobulin Production Sensitizes Myeloma Cells for Proteasome Inhibition

Silke Meister1, Ulrich Schubert3, Kirsten Neubert1, Kai Herrmann4, Renate Burger5, Martin Gramatzki5, Sabine Hahn3, Sandra Schreiber3, Sabine Wilhelm1, Martin Herrmann2, Hans-Martin Jäck4 and Reinhard E. Voll1,2

1 IZKF Research Group 2, Nikolaus-Fiebiger-Center of Molecular Medicine; 2 Department of Internal Medicine 3, University Hospital Erlangen; 3 Institute of Clinical and Molecular Virology; 4 Division of Molecular Immunology, Department of Internal Medicine 3, Nikolaus-Fiebiger-Center, University of Erlangen-Nürnberg, Erlangen, Germany; and 5 Division for Stem Cell Transplantation and Immunotherapy, 2nd Medical Department, University of Kiel, Kiel, Germany

Requests for reprints: Reinhard Voll, IZKF Research Group 2, Nikolaus-Fiebiger-Center, Glückstrasse 6, 91054 Erlangen, Germany. Phone: 49-9131-8539301; Fax: 49-9131-39311; E-mail: rvoll{at}molmed.uni-erlangen.de.

Multiple myeloma is an incurable plasma cell neoplasia characterized by the production of large amounts of monoclonal immunoglobulins. The proteasome inhibitor bortezomib (PS-341, Velcade) induces apoptosis in various malignant cells and has been approved for treatment of refractory multiple myeloma. Inhibition of the antiapoptotic transcription factor nuclear factor-{kappa}B (NF-{kappa}B) apparently contributes to the antitumor effects of bortezomib; however, this mechanism cannot fully explain the exceptional sensitivity of myeloma cells. Extensive protein synthesis as in myeloma cells is inherently accompanied by unfolded proteins, including defective ribosomal products (DRiPs), which need to be degraded by the ubiquitin-proteasome system. Therefore, we hypothesized that the proapoptotic effect of bortezomib in multiple myeloma is mainly due to the accumulation of unfolded proteins in cells with high protein biosynthesis. Using the IgG-secreting human myeloma cell line JK-6L and murine µH-chain–transfected Ag8.H myeloma cells, apoptosis induction upon proteasome inhibition was clearly correlated with the amount of immunoglobulin production. Preferentially in immunoglobulin-high myeloma cells, bortezomib triggered activation of caspases and induction of proapoptotic CHOP, a component of the terminal unfolded protein response induced by endoplasmic reticulum (ER) stress. In immunoglobulin-high cells, bortezomib increased the levels of proapoptotic Bax while reducing antiapoptotic Bcl-2. Finally, IgG-DRiPs were detected in proteasome inhibitor–treated cells. Hence, proteasome inhibitors induce apoptosis preferentially in cells with high synthesis rate of immunoglobulin associated with accumulation of unfolded proteins/DRiPs inducing ER stress. These findings further elucidate the antitumor activities of proteasome inhibitors and have important implications for optimizing clinical applications. [Cancer Res 2007;67(4):1783–92]




This article has been cited by other articles:


Home page
Mol. Cell. ProteomicsHome page
J. M. Koomen, E. B. Haura, G. Bepler, R. Sutphen, E. R. Remily-Wood, K. Benson, M. Hussein, L. A. Hazlehurst, T. J. Yeatman, L. T. Hildreth, et al.
Proteomic Contributions to Personalized Cancer Care
Mol. Cell. Proteomics, October 1, 2008; 7(10): 1780 - 1794.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. T. Nawrocki, J. S. Carew, K. H. Maclean, J. F. Courage, P. Huang, J. A. Houghton, J. L. Cleveland, F. J. Giles, and D. J. McConkey
Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA
Blood, October 1, 2008; 112(7): 2917 - 2926.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
J. van der Vlag and J. H. M. Berden
Proteasome inhibition: a new therapeutic option in lupus nephritis?
Nephrol. Dial. Transplant., September 22, 2008; (2008) gfn536v1.
[Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
H. Gu, X. Chen, G. Gao, and H. Dong
Caspase-2 functions upstream of mitochondria in endoplasmic reticulum stress-induced apoptosis by bortezomib in human myeloma cells
Mol. Cancer Ther., August 1, 2008; 7(8): 2298 - 2307.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. Kraus, E. Malenke, J. Gogel, H. Muller, T. Ruckrich, H. Overkleeft, H. Ovaa, E. Koscielniak, J. T. Hartmann, and C. Driessen
Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis
Mol. Cancer Ther., July 1, 2008; 7(7): 1940 - 1948.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
R. Sitia, G. Palladini, and G. Merlini
Bortezomib in the treatment of AL amyloidosis: targeted therapy?
Haematologica, October 1, 2007; 92(10): 1302 - 1307.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.